Levodopa/Carbidopa Fair-Med Healthcare

Levodopa/Carbidopa, the active ingredient in Levodopa/Carbidopa Fair-Med Healthcare, is a dopamine precursor with peripheral decarboxylase inhibitor presented as an oral tablet for oral use. It is used to manage the motor symptoms of Parkinson's disease and related Parkinsonian syndromes in adult patients.

GNH USA supplies Levodopa/Carbidopa Fair-Med Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and regulatory requirements across EU and global markets.

Levodopa/Carbidopa is indicated for disorders of the dopaminergic system, primarily Parkinsonian conditions.

- Parkinson's disease: improves motor function and reduces rigidity and bradykinesia. - Parkinsonian syndrome: alleviates tremor and gait disturbances associated with secondary Parkinsonism. - Levodopa‑responsive Parkinsonism: provides symptomatic relief in patients whose symptoms improve with levodopa therapy.

Levodopa/Carbidopa may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: upset stomach often occurring at treatment start. - Orthostatic hypotension: dizziness upon standing. - Headache: mild to moderate intensity. - Insomnia: difficulty falling or staying asleep. - Dyspepsia: indigestion or abdominal discomfort. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Dyskinesia: involuntary, erratic movements that may become disabling. - Psychiatric disturbances: hallucinations, confusion, or severe mood changes. - Cardiac arrhythmias: irregular heart rhythms, especially in patients with pre‑existing heart disease. - Neuroleptic malignant syndrome: rare but life‑threatening reaction. - Severe hypotension: marked drop in blood pressure leading to fainting.

When prescribing Levodopa/Carbidopa, clinicians should consider several precautionary measures to ensure safe use.

- Blood pressure monitoring: watch for orthostatic hypotension, especially at treatment initiation. - Psychiatric assessment: monitor for hallucinations, confusion, or mood changes. - Renal function evaluation: dose may need adjustment in severe renal impairment. - Elderly patients: start with low dose and titrate slowly to reduce adverse effects. - Discontinuation: avoid abrupt cessation to prevent withdrawal syndrome. - Store at ambient temperature: keep in original container, protect from moisture and light.

Levodopa/Carbidopa interacts with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Antipsychotics (e.g., haloperidol): antagonize dopamine effect, reducing efficacy. - Pyridoxine (vitamin B6): increases peripheral levodopa metabolism, decreasing central availability.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: additive hypotensive effect. - SSRIs or SNRIs: potential for serotonin syndrome when combined with MAO‑B inhibitors. - Iron or calcium supplements: may impair levodopa absorption; separate dosing by at least 2 hours.